Paragraph Of Results Research Articles

Erratum for Brown-Elliott and Wallace, "In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria".

Volume 66, no. 9, e00689-22, 2022, https://doi.org/10.1128/aac.00689-22. Page 4: the second sentence of the last paragraph of Results should read “The Clinical and Laboratory Standards Institute (CLSI) acceptable range of MICs for both Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922 was 0.016 to 0.12 μg/mL with eravacycline.”

Erratum. Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control. Diabetes 2019;68:441-456.

In the article cited above, in the first paragraph of results, a link to the full set of results was given as https://www.ncbi.nlm.nih.gov/gap. Due …

CORRIGENDUM

In this article, Fig. 2 is incorrect. The corrected Fig. 2 is shown using data from the tissue array samples. The new figure demonstrates the same findings as the original figure. Accordingly, in the paragraph of Materials and methods, the sentence '...surgically resected colon cancer tissues' and 'This study was...research committee' and in the paragraph of Results, the sentence 'Similar results were...tissue array samples' should be deleted. The above changes do not alter the original conclusions of this study. [the original article was published in the International Journal of Oncology 45: 1059-1064, 2014 DOI: 10.3892/ijo.2014.2507].

Altered bone composition in children with vertebral fracture

In [1], the objective was to determine the differences in bone composition in fracture-prone children with and without vertebral fractures, as assessed by Fourier transform infrared spectroscopic imaging (FTIRI) and bone histomorphometry. We collected iliac crest biopsies (n = 24) from children who were suspected of primary osteoporosis. In Materials and Methods in the subsection “Bone biopsies,” we stated, “The iliac crest biopsies were taken mainly within 6 months of the fractures (n = 20), but in some cases up to 12 months had passed since the fracture (n = 4).” However, this statement was unfortunately incorrect. It should say “The iliac crest biopsies were taken mainly within 12 months of the fractures (n = 19), but in some cases up to 18 months had passed since the fracture (n = 5).” As stated above, the duration from the last fracture until the biopsy was longer than reported in the original study in some children. The time between fracture and biopsy is, of course, critical. However, significant differences between children with and without vertebral fractures were still found, and we do not believe this has affected our findings or the conclusions of the study. In Results in the subsection “Bone histomorphometry-based data,” we stated, “Although children with low BV/TV tended to have lower carbonate-to-phosphate ratios, this relationship was not statistically significant (p = .07, Fig. 3A).” After re-checking our data, this is a significant change (p = .033). Therefore, it should be corrected as “Children with low BV/TV had lower carbonate-to-phosphate ratios than children with normal BV/TV (p = .033, Fig. 3A).” A The children with low cancellous bone volume in biopsy (BV/TV Z-score below –1 SD; n = 7) showed lower carbonate-to-phosphate ratio (p < .05) than the children with normal cancellous bone volume (BV/TV Z-score ≥−1 SD; n = 17). The figure presents mean ± SD, and statistical difference (Mann-Whitney U test, *p < .05) are indicated. Further, in the second last paragraph of Results we stated “When the samples were grouped based on turnover rate, carbonate-to-phosphate and carbonate-to-amide I ratios were lower (p < .05, ANOVA) among children with vertebral fracture than among children without vertebral fracture”. Unfortunately this statement is incorrect (p = .056–.106) and should be omitted. These statements have been discussed in the fourth paragraph of Discussion. The statement “In the pooled sample set, the children with low cancellous bone volume in the biopsy tended to show a lower level of carbonate substitution in crystals than children with normal bone volume (p = .07)” should be corrected as “In the pooled sample set, the children with low cancellous bone volume in the biopsy showed a lower level of carbonate substitution in crystals than children with normal bone volume.” The conclusions remain unchanged. The authors regret the mistakes.

Erratum: Single-neuron RNA-Seq: technical feasibility and reproducibility

To the Editor: In our manuscript entitled “Single-neuron RNA-Seq: technical feasibility and reproducibility,” published online on July 6th, 2012, we have made a few serious mistakes which need to be corrected: We referenced several points and quoted statements from a recent study by Okaty et al., but we neither cited the paper nor placed quotation marks on the statements. The full citation should be “Okaty, B. W., Sugino, K., and Nelson, S. B. (2011). Cell type-specific transcriptomics in the brain. J. Neurosci. 31, 6939–6943.” We request to add a citation after “The analysis of each single-cell transcriptome consists of several independent steps” in the first paragraph of Results, as “The analysis of each single-cell transcriptome consists of several independent steps (Okray et al., 2011),” given that these points were previously raised by Okaty et al. We request to add a citation to the first paragraph of Introduction, as “studies of gene expression and function in the brain were restricted to a relatively small number of genes (Luo and Geschwind, 2001; Zhang et al., 2002; Okaty et al., 2011),” given that this points was recently reviewed in the Okaty et al., paper. More importantly, we have made a mistake in quoting sentence from Okray et al., without quotation or citation. We wish to change the following sentence: Moreover, gene expression may be regulated in opposing directions in different cell types, thereby appearing static in composite data. To Moreover, as previously discussed by Okaty et al., “gene expression may be regulated in opposing directions in different cell types, thereby appearing static in composite data (Okaty et al., 2011).” We apologize to the readers of Frontiers in Genetics and to the authors of the Okaty et al., manuscript, for our failure to correct these mistakes during the review process of our manuscript.

Corrigendum

Diabetes, Obesity and MetabolismVolume 14, Issue 4 p. 385-385 Free Access Corrigendum This article corrects the following: Improved cardiovascular health following a progressive walking and dietary intervention for type 2 diabetes S. T. Johnson, G. J. Bell, L. J. McCargar, R. S. Welsh, R. C. Bell, Volume 11Issue 9Diabetes, Obesity and Metabolism pages: 836-843 First Published online: July 10, 2009 First published: 05 March 2012 https://doi.org/10.1111/j.1463-1326.2011.01501.xCitations: 1AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat In Johnson ST et al. [1], there were errors in reporting. Please refer to the corrections outlined below: • In the abstract, an increase in average total daily steps was incorrectly stated as 1562 (95% confidence interval: 303–2821, p = 0.02). It should have been 1688 (95% confidence interval: 330–3040, p = 0.02). • In the second paragraph of Results, it was incorrectly stated that participants increased walking by 1562 steps/day (95% confidence interval: 302–2821, p = 0.02). It should have been 1688 steps/day (95% confidence interval: 330–3040, p = 0.02). • In Table 2, the 95% CI for steps/day was incorrectly presented as 1,562 (303–2821). It should have been 1,688 (330–3040). The authors apologize for these errors. Reference 1 Johnson ST, Bell GJ, McCargar LJ, Welsh RS, Bell RC. Improved cardiovascular health following a progressive walking and dietary intervention for type 2 diabetes. Diabetes Obes Metab 2009; 11: 836– 843. Citing Literature Volume14, Issue4April 2012Pages 385-385 ReferencesRelatedInformation

Erratum: Proposed Standard Weight (Ws) Equation and Standard Length Categories for Suwannee Bass (volume 30:983–988)

Please make the following corrections in a recent issue of this journal: Volume 30(4), August 2010: “Proposed Standard Weight (Ws) Equation and Standard Length Categories for Suwannee Bass,” by Timothy F. Bonvechio, Kimberly I. Bonvechio, and Richard L. Cailteux, pages 983–988. Page 983. The third sentence of the Abstract should read as follows: The resulting Ws equations were log10 W = −5.455 + 3.260 × log10 L and log10 W = −0.106 − 1.363 × log10 L + 0.995 × (log10 L)2 (where W is weight in grams and L is TL in millimeters) for the RLP and quadratic EmP techniques, respectively. Page 985. The second sentence of the second paragraph of Results and Discussion should read as follows: The resulting standard weight equations were determined as for metric units (where W is weight in grams and L is TL in millimeters) and for English units (where weight is in pounds and TL in inches). Page 985. The sixth sentence of the second paragraph of Results and Discussion should read as follows: The EmP-Q standard weight equations for the species are and for metric and English units, respectively.

Further research on Xyrem®/sodium oxybate treatment of patients with obstructive sleep apnea is needed

To the editor: We are happy to respond to Zvosec and colleagues about this paper as we have recently done for their concerns about our related paper [1]. The number of patients with adverse effects in the Phase 1 single dose Xyrem® study was listed in the original manuscript (last paragraph of Results). A tabular format was not used. Dr Zvosec and colleagues continue to raise concerns about the actual number of patients who withdrew due to adverse events (AEs). In the Phase 1 study “ Nine patient withdrew due to adverse evenrts (AEs) and one for protocol violation.” (last sentence, 1st paragraph Results [1]). There was an error in numbers reported later in that paper as correctly noted by Zvosec and we addressed that in our reply to them previously. Concerning the current paper, Figure 1 lists 10 patients excluded and suggests all were excluded due toAEs. In fact this should be 9AEs plus 1 protocol violation as noted (vide supra) Adverse events were collected at each visit and coded using Medical Dictionary for Regulatory Activities dictionary (MedDRA version 8.0) (this was noted in the Legend of Table 3). As Zvosec will know, any and all adverse events, however trivial and even when not related to medications, are reported in any drug safety study. In this case, the event listed under the headings 1) “injury, poisoning, and procedural complication” and 2) “limb injury” are one in the same and was not related to Xyrem® With respect to reporting of AHI and SaO2, we reported mean and standard deviations for these values. Given that the inclusion criteria already constrained the ranges for AHI and SaO2 and given that the mean and standard deviations were decreased for AHI (unchanged for SaO2) with treatment, we did not think that including ranges for these values would add substantially to the data. We agree that not withstanding these results, physicians still need to exercise caution and be aware of potential respiratory depression when prescribing Xyrem® to patient with or at risk for sleep disordered breathing. We do not disagree, in fact have previously stated [2], that there may be a subset of patients that are more susceptible to Xyrem® and agree that a prospective study of extended use of doses of 9 g per night will go a long way to allay fears of respiratory depression.

Corrigendum

CorrigendaCorrigendumPublished Online:01 May 2010https://doi.org/10.1152/jn.z9k-0125-corr.2010Original articleMoreSectionsPDF (20 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmailWeChat Volume 103, March 2010Meenderink SWF, van der Heijden M. Reverse Cochlear Propagation in the Intact Cochlea of the Gerbil: Evidence for Slow Traveling Waves. J Neurophysiol 103: , 2010; doi:10.1152/jn.00899.2009; http://jn.physiology.org/cgi/content/full/103/3/1448.During production two errors in numerical values were not corrected. These are as follows. In the last paragraph of results, the second sentence of the paragraph should read (boldface added here to highlight change):“The total ear canal to ear canal round-trip (722 μs; 4.4 cycles) consists of a forward f1 stimulus delay through the middle ear (166 μs; 0.2 cycles), and the cochlea (at most 84 μs; 0.5 cycles); a reverse cochlear delay (≥399 μs; 2.5 cycles); and a reverse middle ear delay (73 μs; 0.4 cycles).”In the 2nd paragraph of discussion, in the section titled “Middle ear delays,” the first sentence should read (boldface added here to highlight change):“The combined CM and ear-canal sound pressure recordings also allowed us to calculate the group delays associated with forward and reverse propagation in the middle ear (166 ± 54 and 73 ± 22 μs, respectively).”This article has no references to display. Download PDF Previous Back to Top Next FiguresReferencesRelatedInformationRelated ArticlesReverse Cochlear Propagation in the Intact Cochlea of the Gerbil: Evidence for Slow Traveling Waves 01 Mar 2010Journal of Neurophysiology More from this issue > Volume 103Issue 5May 2010Pages 2933-2933 Copyright & PermissionsCopyright © 2010 the American Physiological Societyhttps://doi.org/10.1152/jn.z9k-0125-corr.2010History Published online 1 May 2010 Published in print 1 May 2010 Metrics

Erratum to: Utility of a single adjusting compartment: a novel methodology for whole body physiologically-based pharmacokinetic modelling

After our work was published, we found that some of the terms in the equations were incorrect and that there were some typographical errors in the abbreviations.In the section 'Single adjusting compartment' in Materials and Methods, VS should be VSAC.In the last paragraph of Results, QSAC should be QSAC.The correct equations are included in this article.These corrections will not affect the results of this study.

Correction to "Magnetic Resonance Imaging of Electrical Conductivity in the Human Brain" [Oct 05 4203-4205

In the above titled paper (ibid., vol. 41, no. 10, pp. 4203-4205, Oct 05), equation (2) contains an error. The corrected equation is presented here. In the second paragraph of Results, incorrect MC values were listed. These are corrected here. A corrected version of Fig. 2 is also presented here.

REPLY

REPLY

Correction

HomeCirculationVol. 101, No. 5Correction Free AccessCorrectionPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCorrectionPDF/EPUBCorrection Originally published8 Feb 2000https://doi.org/10.1161/01.CIR.101.5.584Circulation. 2000;101:584This article corrects the followingAcute Anti-Ischemic Effect of Testosterone in Men With Coronary Artery DiseaseIn the article by Rosano et al that appeared in a previous issue of the journal (Circulation. 1999;99:1666–1670 ), the units of measurement reported for testosterone levels were incorrect. These units should be ng/mL, not mg/dL. This requires changes in the text, Table 3, and Figure 2.Under Methods: Testosterone Analysis, the last sentence should read: “The lower limit of normal testosterone levels in men by this method is 9 ng/mL.”The seventh sentence of the second paragraph of Results should read: “Plasma testosterone levels increased significantly (by 2 orders of magnitude) after intravenous testosterone administration (Table 3), and no difference in the hormonal plasma levels was observed between samples obtained before and after exercise (527±342 versus 518±337 ng/mL, P=NS).”The correct versions of Table 3 and Figure 2 appear below. Table 3. Plasma Hormone Levels After Testosterone and PlaceboPlaceboTestosteroneTestosterone, ng/mL9.75±1.76527±342*Estrone, pg/mL20±1520±18FSH, mUI/mL5.2±2.75.3±3LH, mUI/mL2.6±1.22.5±1.117β-Estradiol, pmol/L121±24120±25Estradiol/testosterone, ×10−38.1±0.54.2±1.4*SHBG, nmol/L42 ±1042±12FSH indicates follicule-stimulating hormone; LH, luteinizing hormone; and SHBG, sex hormone–binding globulin.Download figureDownload PowerPoint Figure 2. Correlation between baseline plasma testosterone levels and improvement in time to 1-mm ST-segment depression and total exercise time after intravenous testosterone administration. A significant inverse correlation was found between baseline plasma levels of testosterone and improvement in time to 1-mm ST-segment depression, whereas no correlation was found with improvement in total exercise time. Dotted line represents lower limit of normal testosterone values in men. Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesAcute Anti-Ischemic Effect of Testosterone in Men With Coronary Artery DiseaseGiuseppe M. C. Rosano, et al. Circulation. 1999;99:1666-1670 February 8, 2000Vol 101, Issue 5 Advertisement Article InformationMetrics Copyright © 2000 by American Heart Associationhttps://doi.org/10.1161/01.CIR.101.5.584 Originally publishedFebruary 8, 2000 PDF download Advertisement

Vanadate causes hypokalemic distal renal tubular acidosis

Pages F449–F453: E. Dafnis, M. Spohn, B. Lonis, N. A. Kurtzman, and S. Sabatini. “Vanadate causes hypokalemic distal renal tubular acidosis.” The value for urine anion gap in NH4Cl-treated animals on page F450 (last sentence in first paragraph of results), as well as on page F51 (Table 2, last value in last line), should be -82 ± 7 meq/l instead of -232 ± 27 meq/l.

Vanadate causes hypokalemic distal renal tubular acidosis

Pages F449–F453: E. Dafnis, M. Spohn, B. Lonis, N. A. Kurtzman, and S. Sabatini. “Vanadate causes hypokalemic distal renal tubular acidosis.” The value for urine anion gap in NH4Cl-treated animals on page F450 (last sentence in first paragraph of results), as well as on page F51 (Table 2, last value in last line), should be -82 ± 7 meq/l instead of -232 ± 27 meq/l.

Clinical Effectiveness of the Du Pont acaMeasurement of Creatine Cinase MB in Serum from Patients in a Coronary-Care Unit

Abstract Vol. 30 p 1553, Insert the symbol "○" in the sublegend to Fig. 1, third line, to read "...method: ○, activity..." Vol. 31 p 572, middle of right column: delete the three repeated lines of type. p 575, in "Table 1 (continued)," the first column heading hould read "Sample size, ND = ND·" p 616, left column, first text paragraph: the second sentence should read, "This nonlinear protein binding explains the dependence of renal clearance of disopyramide on total disopyramide concentration in serum and the lack of dependence of renal clearance on the concentration of free disopyramide (5). Furthermore, the pharmacological response to this drug is better correlated with the concentration of the free drug in serum than with its total concentration (4, 6); we thus condude that both the free fraction and the total concentration should be measured when one is monitoring arrhythmic patients who are being treated with his drug." p 617, left column: delete the two lines of text following the first paragraph of Results, and delete the three lines following the second paragraph. p 640: Three lines are missing in the section on Ferritin standards, as follows: "Ferritin from human liver, 9.7 µg per bottle, i.e., 9.1 mg/L (National Institute for Biological Standards and Controls, Hampstead-Holly Hill, London, reference 80/602)." p 641, left column, third line of text at bottom: "3988" should read "398.8" and "4140" should read "414.0." p 647, middle column, preceding the 10th line from bottom, insert: "Using this method, we found the ... " p 655, right column: the concluding paragraph (preceding the references) should read as follows: "Our results indicate that assay of serum SHBG is of value in the analysis of risk factors for mortality in post-menopausal women. Whether low SHBG concentration in these women primarily reflects androgen excess, estrogen deficiency, or other endocrine or metabolic changes remains a subject for further study, as does the relationship to adipose tissue distribution."